Blueprint Medicines Q2 EPS $(2.19) Beats $(2.58) Estimate, Sales $57.57M Beat $45.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Blueprint Medicines reported Q2 earnings per share of $(2.19), beating the analyst consensus estimate of $(2.58) by 15.12%. This is an 18.28% increase over the same period last year. The company also reported quarterly sales of $57.57 million, beating the analyst consensus estimate of $45.00 million by 27.93%. This is a 57.52% increase over the same period last year.
August 04, 2023 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Blueprint Medicines reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could increase investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100